Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials

American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edition: DSM-5. American Psychiatric Publishing, Arlington, TX Anderson GD (2008) Gender differences in pharmacological response. Int Rev Neurobiol 83:1–10. https://doi.org/10.1016/S0074-7742(08)00001-9 Berlanga C, Flores-Ramos M (2006) Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 95(1–3):119–123. https://doi.org/10.1016/j.jad.2006.04.029 Bigos KL, Pollock BG, Stankevich BA, Bies RR (2009) Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. Gend Med 6(4):522–543. https://doi.org/10.1016/j.genm.2009.12.004 Cassano P, Soares CN, Cusin C, Mascarini A, Cohen LS, Fava M (2005) Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine. Psychother Psychosom 74(6):362–365. https://doi.org/10.1159/000087783 Cuijpers P, Weitz E, Twisk J, Kuehner C, Cristea I, David D, DeRubeis RJ, Dimidjian S, Dunlop BW, Faramarzi M, Hegerl U, Jarrett RB, Kennedy SH, Kheirkhah F, Mergl R, Miranda J, Mohr DC, Segal ZV, Siddique J, Simons AD, Vittengl JR, Hollon SD (2014) Gender as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression: an “individual patient data” meta-analysis. Depression Anxiety 31(11):941–951. https://doi.org/10.1002/da.22328 Dalla C, Pitychoutis PM, Kokras N, Papadopoulou-Daifoti Z (2010) Sex differences in animal models of depression and antidepressant response. Basic Clin Pharmacol Toxicol 106(3):226–233. https://doi.org/10.1111/j.1742-7843.2009.00516.x Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC (2018) Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiat 75(2):139–148. https://doi.org/10.1001/jamapsychiatry.2017.3739 Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, Cubala WJ, Bitter I, Blier P, Shelton RC, Molero P, Drevets WC, Singh JB (2019) Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 76(9):893–903. Advance online publication. https://doi.org/10.1001/jamapsychiatry.2019.1189 Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, Vitagliano D, Blier P, Fava M, Liebowitz M, Ravindran A, Gaillard R, Ameele H, Preskorn S, Manji H, Hough D, Drevets WC, Singh JB (2019) Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol 22(10):616–630. https://doi.org/10.1093/ijnp/pyz039 Fernández-Guasti A, Fiedler JL, Herrera L, Handa RJ (2012) Sex, stress, and mood disorders: at the intersection of adrenal and gonadal hormones. Horm Metab Res 44(8):607–618. https://doi.org/10.1055/s-0032-1312592 Frank E, Carpenter LL, Kupfer DJ (1988) Sex differences in recurrent depression: are there any that are significant? Am J Psychiatry 145(1):41–45. https://doi.org/10.1176/ajp.145.1.41 Freeman MP, Walker R, Laughren TP, Miller KK, Fava M (2013) Female reproductive life cycle and hormones: methodology to improve clinical trials. J Clin Psychiatry 74(10):1018–1021. https://doi.org/10.4088/JCP.13com08742 Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M (2019) Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res 110:166–171. https://doi.org/10.1016/j.jpsychires.2019.01.010 Grigoriadis S, Kennedy SH, Bagby RM (2003) A comparison of antidepressant response in younger and older women. J Clin Psychopharmacol 23(4):405–407. https://doi.org/10.1097/01.jcp.0000085415.08426.c6 Hasin DS, Goodwin RD, Stinson FS, Grant BF (2005) Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 62(10):1097–1106. https://doi.org/10.1001/archpsyc.62.10.1097 Jacoby R, Lunn A, Ardern M, Bergmann K, Conway J, Cooling N, Davies G, Fisk J, Gehlhaar E, Harrison-Read P, Hawley R, Jacoby R, Jones R, Levy R, MacDonald A, Naguib M, Oppenheimer C, Philpot M, Philpott R, Pitt B, Price M, Robinson J, Silverman M, Simons R, Slattery Z, Staley C, Taws E, Tym E, White M (1993) How long should the elderly take antidepressants? A double-blind placebo-controlled study of continuation/prophylaxis therapy with dothiepin. Br J Psychiatry 162:175–182. https://doi.org/10.1192/bjp.162.2.175 Khan A, Brodhead AE, Schwartz KA, Kolts RL, Brown WA (2005) Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol 25(4):318–324. https://doi.org/10.1097/01.jcp.0000168879.03169.ce Kim J, Farchione T, Potter A, Chen Q, Temple R (2019) Esketamine for treatment-resistant depression—first FDA-approved antidepressant in a new class. N Engl J Med 381(1):1–4. https://doi.org/10.1056/NEJMp1903305 Kornstein SG, Schatzberg AF, Thase M, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Harrison WM, Keller MB (2000) Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 157(9):1445–1452. https://doi.org/10.1176/appi.ajp.157.9.1445 Kornstein SG, Clayton AH, Soares CN, Padmanabhan SK, Guico-Pabia CJ (2010) Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. J Clin Psychopharmacol 30(3):294–299. https://doi.org/10.1097/JCP.0b013e3181dcb594 Kornstein SG, Toups M, Rush AJ, Wisniewski SR, Thase ME, Luther J, Warden D, Fava M, Trived MH (2013) Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. J Womens Health 22(2):121–131. https://doi.org/10.1089/jwh.2012.3479 Kornstein SG, Pedersen RD, Holland PJ, Nemeroff CB, Rothschild AJ, Thase ME, Trivedi MH, Ninan PT, Keller MB (2014) Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study. J Clin Psychiatry 75(1):62–68. https://doi.org/10.4088/JCP.12m07841 Kornstein S, Chang CT, Gommoll CP, Edwards J (2018) Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials. Int Clin Psychopharmacol 33(4):217–223. https://doi.org/10.1097/YIC.0000000000000217 Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE (2006) Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials. J Clin Psychiatry 67(5):761–770. https://doi.org/10.4088/jcp.v67n0510 Leon AC, Olfson M, Portera L, Farber L, Sheehan DV (1997) Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 27(2):93–105. https://doi.org/10.2190/T8EM-C8YH-373N-1UWD Marcus SM, Young EA, Kerber KB, Kornstein S, Farabaugh AH, Mitchell J, Wisniewski SR, Balasubramani GK, Trivedi MH, Rush AJ (2005) Gender differences in depression: findings from the STAR*D study. J Affect Disord 87(2–3):141–150. https://doi.org/10.1016/j.jad.2004.09.008 Montgomery SA, Möller HJ (2009) Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol 24(3):111–118. https://doi.org/10.1097/YIC.0b013e32832a8eb2 Noordam R, Aarts N, Tiemeier H, Hofman A, Stricker BH, Visser LE (2015) Sex-specific association between antidepressant use and body weight in a population-based study in older adults. J Clin Psychiatry 76(6):e745–e751. https://doi.org/10.4088/JCP.13m08896 Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, Hough D, Manji H, Drevets WC, Sanacora G, Steffens DC, Adler C, McShane R, Gaillard R, Wilkinson ST, Singh JB (2020) Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3. Am J Geriatr Psychiatry 28(2):121–141. https://doi.org/10.1016/j.jagp.2019.10.008 Pinto-Meza A, Usall J, Serrano-Blanco A, Suárez D, Haro JM (2006) Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference?. J Affect Disord 93(1–3):53–60. https://doi.org/10.1016/j.jad.2006.02.010 Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB (2019) Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 176(6):428–438. https://doi.org/10.1176/appi.ajp.2019.19020172 Preskorn SH (2013) Declining differences in response rates with antidepressants versus placebo: a modest proposal for another contributing cause. J Psychiatr Pract 19(3):227–233. https://doi.org/10.1097/01.pra.0000430506.37144.d1 (PMID: 23653079) Quitkin FM, Stewart JW, McGrath PJ, Taylor BP, Tisminetzky MS, Petkova E, Chen Y, Ma G, Klein DF (2002) Are there differences between women’s and men’s antidepressant responses? Am J Psychiatry 159(11):1848–1854. https://doi.org/10.1176/appi.ajp.159.11.1848 Schneider LS, Small GW, Clary CM (2001) Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry 9(4):393–399 (PMID: 11739065) Seedat S, Scott KM, Angermeyer MC, Berglund P, Bromet EJ, Brugha TS, Demyttenaere K, de Girolamo G, Haro JM, Jin R, Karam EG, Kovess-Masfety V, Levinson D, Medina Mora ME, Ono Y, Ormel J, Pennell BE, Posada-Villa J, Sampson NA, Williams D, Kessler RC (2009) Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. Arch Gen Psychiatry 66(7):785–795. https://doi.org/10.1001/archgenpsychiatry.2009.36 Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(suppl 20):22–33; quiz 34–57. PMID: 9881538 Spitzer RL, Kroenke K, Williams JB (1999) Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA 282(18):1737–1744. https://doi.org/10.1001/jama.282.18.1737 Spitzer RL, Kroenke K, Williams JB, Löwe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166(10):1092–1097. https://doi.org/10.1001/archinte.166.10.1092 Spravato (esketamine) Summary of product characteristics (2020) https://www.medicines.org.uk/emc/product/10977/smpc. Accessed 3 May 2021. SpravatoTM (esketamine) nasal spray Prescribing Information. © 2020 Janssen Pharmaceutical Companies. Sramek JJ, Murphy MF, Cutler NR (2016) Sex differences in the psychopharmacological treatment of depression. Dialogues Clin Neurosci 18(4):447–457. https://doi.org/10.31887/DCNS.2016.18.4/ncutler Thase ME, Entsua R, Cantillon M, Kornstein SG (2005) Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (larchmt) (2002) 14(7):609–616. https://doi.org/10.1089/jwh.2005.14.609 Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young, AH, Kasper S, Sulaiman AH, Li CT, Paik JW, Manji H, Hough D, Grunfeld J, Jeon HJ, Wilkinson ST, Drevets WC, Singh JB (2020) Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry 81(3):19m12891. https://doi.org/10.4088/JCP.19m12891 Williams JB, Kobak KA (2008) Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). Br J Psychiatry 192(1):52–58. https://doi.org/10.1192/bjp.bp.106.032532 Yang SJ, Kim SY, Stewart R, Kim JM, Shin IS, Jung SW, Lee MS, Jeong SH, Jun TY (2011) Gender differences in 12-week antidepressant treatment outcomes for a naturalistic secondary care cohort: the CRESCEND study. Psychiatry Res 189(1):82–90. https://doi.org/10.1016/j.psychres.2010.12.027 Young EA, Kornstein SG, Marcus SM, Harvey AT, Warden D, Wisniewski SR, Balasubramani GK, Fava M, Trivedi MH, Rush JA (2009) Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res 43(5):503–511. https://doi.org/10.1016/j.jpsychires.2008.07.002